Electromed, Inc. reported significant financial growth in its latest quarterly results, with net revenues reaching $18.575 million for the three months ended March 31, 2026, a 18.4% increase from $15.684 million in the same period last year. For the nine months ending March 31, 2026, revenues totaled $54.359 million, up 16.6% from $46.607 million in the prior year. The company’s net income also saw a substantial rise, increasing by 58.8% to $3.003 million for the quarter and 48.1% to $7.900 million for the nine-month period. This growth in profitability was attributed to higher sales volumes and improved revenue per approval, particularly in the homecare segment, which accounted for $16.732 million of the quarterly revenue.
The company experienced notable changes in its operational metrics, with the average number of homecare field sales representatives increasing to 57, contributing to higher sales productivity. The homecare revenue alone increased by $2.630 million, or 18.6%, for the quarter, driven by both volume and higher net revenues per approval. Hospital revenue also grew significantly, up 42.5% to $1.032 million for the quarter, reflecting increased demand and a focus on expanding sales in that market. However, other revenue sources declined, primarily due to reduced purchases from international distributors.
Electromed's balance sheet showed total assets of $59.474 million as of March 31, 2026, compared to $53.802 million at the end of the previous fiscal year. Current assets increased to $50.228 million, bolstered by higher cash and accounts receivable. The company’s total liabilities decreased slightly to $10.307 million, resulting in total shareholders' equity rising to $49.167 million, up from $43.209 million. The company also reported a cash flow from operating activities of $6.671 million for the nine months ended March 31, 2026, indicating strong operational cash generation.
Strategically, Electromed continues to focus on enhancing its product offerings, including the SmartVest Clearway® Airway Clearance System, which received FDA clearance in November 2022. The company is also actively managing its share repurchase program, having repurchased shares worth $3.918 million under a $10 million authorization. Looking ahead, Electromed anticipates continued growth driven by its expanding sales force and product adoption, while maintaining a strong liquidity position with approximately $40 million in working capital and available credit under its $10 million revolving line of credit.
Overall, Electromed, Inc. is positioned for ongoing growth, supported by its innovative product line and strategic investments in sales and marketing. The company remains optimistic about its future performance, although it acknowledges potential risks related to market conditions and regulatory changes that could impact its operations.
About Electromed, Inc.
Electromed, Inc. develops, manufactures, and markets the SmartVest airway clearance system, primarily serving patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions. Its products use high-frequency chest wall oscillation (HFCWO) to improve respiratory function, reduce infections, and lower healthcare costs. The company employs a direct-to-patient and provider sales model, focusing on clinical evidence, reimbursement support, and product innovation in the U.S. and select international markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.